Nutrition, wellness, weight loss, and calmer healthy living.
Explore a little further

FDA

Stories and perspectives from Breathing.Food.

From Breathing.Food

12 stories shown · Newest added
Breathing.Food

New Gene-Editing Therapy VERVE-102 Shows Promise in Lowering LDL Cholesterol

The experimental gene-editing drug VERVE-102, developed by Eli Lilly, has demonstrated the potential to reduce LDL cholesterol levels by up to 62% in early trials. This therapy aims to silence the PCSK9 gene, which plays a role in cholesterol regulation. While the results are pr…

More perspectives

Across our publications

A selection of related stories